Comparison of the Emit immunoassay with HPLC for therapeutic drug monitoring of mycophenolic acid in pediatric renal-transplant recipients on mycophenolate mofetil therapy

Clinical Chemistry

Volumn 48, Issue 3, 2002, Pages 517-525

  Weber, Lutz T ^a   Shipkova, Maria ^a   Armstrong, Victor W ^a   Wagner, Natalie ^a   Schütz, Ekkehard ^a   Mehls, Otto ^a   Zimmerhackl, Lothar B ^a   Oellerich, Michael ^a   Tönshoff, Burkhard ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CROSS REACTING ANTIBODY; CYCLOSPORIN A; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE;

ADOLESCENT; ANEMIA; AREA UNDER THE CURVE; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG MONITORING; ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE; FEMALE; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; KIDNEY TRANSPLANTATION; MALE; PEDIATRIC SURGERY; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VALIDATION PROCESS;

EID: 0036177714     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/48.3.517     Document Type: Article

References (37)

1. The use of mycophenolate mofetil in transplant recipients
2. Trends in immunosuppressive therapy: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS)
3. Pharmacokinetics of mycophenolate mofetil (RS 61443). A short review
4. Mycophenolic acid binding to human serum albumin: Characterization and relation to pharmacodynamics
5. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients
6. Identification of glucoside and carboxyllinked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil
7. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil
8. The acyl glucuronide metabolite of mycophenolic acid inhibits the proliferation of human mononuclear leukocytes
9. Therapeutic monitoring of mycophenolic acid. A consensus panel report
10. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation
11. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation
12. Mycophenolic acid concentrations are associated with cardiac allograft rejection
13. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: Importance of mycophenolic acid therapeutic drug monitoring
14. Therapeutic drug monitoring of mycophenolic acid: Comparison of HPLC and immunoassay reveals new MPA metabolites
15. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay
16. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite
17. Area under the plasma concentration-time curve for total, but not for free, mycophenolic acid increases in the stable phase after renal transplantation: A longitudinal study in pediatric patients
18. Mycophenolate mofetil in pediatric renal transplantation without induction therapy: Results after 12 months of treatment
19. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: A report of the German Study Group on Mycophenolate Mofetil Therapy
20. The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents
21. Mycophenolate mofetil (MMF) in pediatric renal transplantation
22. A formula to estimate the approximate surface area if height and weight be known
23. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure
24. Determination of the acyl glucuronide metabolite of mycophenolic acid in human plasma by HPLC and Emit
25. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring
26. International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology
27. A method of comparing the areas under receiver operating characteristic curves derived from the same cases
28. Pharmacokinetics of the pharmacologically active acyl glucuronide metabolite (AcMPAG) of mycophenolic acid (MPA) in pediatric renal transplant recipients
29. Correlation of mycophenolic acid pharmacokinetic parameters with side effects in kidney transplant patients treated with mycophenolate mofetil
30. Pharmacokinetic basis for the efficient and safe use of low-dose mycophenolate mofetil in combination with tacrolimus in kidney transplantation
31. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection: A report of the European Tacrolimus Multicenter Renal Study Group
32. Evidence that tacrolimus augments the bioavailability of mycophenolate mofetil through the inhibition of mycophenolic acid glucuronidation
33. Coadministration of tacrolimus and mycophenolate mofetil does not increase mycophenolic acid (MPA) exposure, but coadministration of cyclosporine inhibits the enterohepatic recirculation of MPA, thereby decreasing its exposure
34. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure
35. The impact of routine mycophenolate mofetil drug monitoring on the treatment of cardiac allograft rejection
36. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients